A Randomized Phase 2 Study of Ixabepilone Plus Carboplatin and Paclitaxel Plus Carboplatin in Advanced Nonsmall-Cell Lung Cancer

Exclusion Criteria

• •Uncontrolled brain metastases
• •Peripheral neuropathy greater than Grade 1
• •Fewer than 4 weeks from prior radiation therapy or locoregional surgeries to randomization date (less than 1 week from focal/palliative radiotherapy or minor surgery)
• •Any concurrent malignancy other than nonmelanoma skin cancer or carcinoma in situ of the cervix
• •Known HIV-positive status
• •Absolute neutrophil count lower than 1500 cells mm\^3
• •Total bilirubin level higher than upper limit of normal (ULN) as defined by the institution (with the exception of elevation due to Gilbert's syndrome)
• •Aspartate transaminase or alanine transaminase level higher than 2.5\*ULN
• •Serum creatine level of 1.5 mg/dL or higher
• •Renal function with a creatinine clearance of less than 50 mL/min (as calculated with the Cockcroft and Gault equation)
• •Any prior antineoplastic systemic regimens.